Sci Transl Med:雌二醇或能有助预防ARX基因突变X连锁婴儿痉挛症发作

2014-01-28 佚名 不详

美国一项最新研究发现,性激素雌二醇能够减少甚至阻止一种严重儿童癫痫——x连锁婴儿痉挛症的发作。研究人员推测,这种激素可能可以修复改善诱发癫痫发作的问题神经元的功能。 雌二醇是一种主要的雌激素,负责调节女性特征、生理周期等。这种激素也是由大脑神经元调控合成的,因此具有保护神经元的天然特性。 据美国科学促进会网站报道,美国贝勒医学院的研究人员利用小鼠进行了相关实验。

美国一项最新研究发现,性激素雌二醇能够减少甚至阻止一种严重儿童癫痫——x连锁婴儿痉挛的发作。研究人员推测,这种激素可能可以修复改善诱发癫痫发作的问题神经元的功能。

雌二醇是一种主要的雌激素,负责调节女性特征、生理周期等。这种激素也是由大脑神经元调控合成的,因此具有保护神经元的天然特性。

据美国科学促进会网站报道,美国贝勒医学院的研究人员利用小鼠进行了相关实验。这些小鼠都携带有与罹患严重癫痫发作的婴儿相同的基因突变。在实验中,小鼠所接受的雌二醇剂量水平与那些通过母体血液输送给胎儿的剂量水平类似。

实验显示,雌二醇可以在疾病进程的早期改变小鼠大脑的神经元回路从而防止癫痫发作。研究人员还发现,要想取得更好的预防效果,小鼠必须在出生后不久就接受雌二醇。如果延迟至小鼠30天大的时候,雌二醇就失去了防止其癫痫发作的效果。

研究人员认为,这可能主要是因为在小鼠生命跨过某一时间节点后,大脑细胞就会停止对雌二醇刺激作出反应。在生命发育早期,神经元前体会迁移到它们在大脑中的最终位置并形成新的连接,如果在这一早期过程中引入雌二醇等类似激素,就会产生良性影响,对日后成年时的大脑功能也有益处。

研究人员也表示,这种雌激素对大脑神经元的影响是自限性的,而且施加影响的窗口期会很快关闭。不过,这一研究结果仍表明,人们或许有可能利用雌二醇对婴儿大脑的发育施加正面刺激。

原始出处:

Olivetti PR, Maheshwari A, Noebels JL.Neonatal estradiol stimulation prevents epilepsy in arx model of x-linked infantile spasms syndrome.Sci Transl Med. 2014 Jan 22;6(220):220ra12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]
    2014-02-05 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]
    2014-01-30 hxzhang
  5. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]
    2014-01-30 apoenzyme
  6. [GetPortalCommentsPageByObjectIdResponse(id=2067139, encodeId=6ef7206e139de, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Sep 02 09:58:00 CST 2014, time=2014-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656600, encodeId=6dac1656600ed, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Feb 05 22:58:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665424, encodeId=2fbf166542475, content=<a href='/topic/show?id=f6fd1891e53' target=_blank style='color:#2F92EE;'>#X连锁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18917, encryptionId=f6fd1891e53, topicName=X连锁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb025960146, createdName=12498ebem27暂无昵称, createdTime=Tue Dec 09 05:58:00 CST 2014, time=2014-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299409, encodeId=bced1299409c6, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311729, encodeId=73181311e29de, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606102, encodeId=87c21606102b1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 30 06:58:00 CST 2014, time=2014-01-30, status=1, ipAttribution=)]

相关资讯

BMC Cancer:雌二醇抑制microRNA诱导乳腺癌细胞增殖

在对雌激素有反应的MCF-7细胞中,雌二醇(E2)结合雌激素受体α参与调控细胞增殖和生存基因的转录。微小RNA(miRNA的)已经成为重要的转录后基因表达调控因子。 近日,BMC Cancer杂志上的一项研究探讨了miRNA是否参与激素调节雌激素受体基因的表达。研究人员采用Western blot和定量PCR分别来确定雌激素应答基因和miRNA的表达。荧光素酶报告基因检测和转染miRNA的模仿或